Global Mitral Valve Intervention Market Growth 2023-2029

Global Mitral Valve Intervention Market Growth 2023-2029

The mitral valve is composed of the mitral valve annulus, mitral valve leaflets, chordae tendineae and papillary muscles. One part of the mitral valve leaflet including the anterior and posterior leaflets is connected to the mitral valve annulus, and the other end is connected to the chordae tendineae, while the chordae tendineae is connected to the mitral valve annulus. It is connected to the papillary muscle and constitutes the structural integrity of the mitral valve. The integrity of mitral valve function requires that the size of the mitral valve annulus is appropriate, the valve leaflet structure is complete, the papillary muscles contract and stretch the chordae tendineae to support the valve leaflets, the left ventricular muscle contraction produces appropriate closing force, and the ventricular morphology and function are normal.
LPI (LP Information)' newest research report, the “Mitral Valve Intervention Industry Forecast” looks at past sales and reviews total world Mitral Valve Intervention sales in 2022, providing a comprehensive analysis by region and market sector of projected Mitral Valve Intervention sales for 2023 through 2029. With Mitral Valve Intervention sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Mitral Valve Intervention industry.
This Insight Report provides a comprehensive analysis of the global Mitral Valve Intervention landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Mitral Valve Intervention portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Mitral Valve Intervention market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Mitral Valve Intervention and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Mitral Valve Intervention.
The global Mitral Valve Intervention market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Mitral Valve Intervention is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Mitral Valve Intervention is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Mitral Valve Intervention is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Mitral Valve Intervention players cover Edwards Lifesciences, Abbott, CardioSolution, NeoChord, Mitralign, Medtronic, Boston Scientific, Mitralix and Shanghai Hanyu Medical Technology, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Mitral Valve Intervention market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Replacement Product
Repair Product
Annulus Products
Segmentation by application
Transapical
Via Stock and Via Interstitial
Right Internal Jugular Vein
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Edwards Lifesciences
Abbott
CardioSolution
NeoChord
Mitralign
Medtronic
Boston Scientific
Mitralix
Shanghai Hanyu Medical Technology
Valgen Holding Corporation
NeoChord
CoreMedic
Babic Chord
Gore Medical
Valtech Cardio
Transcardiac
ChoRe
AVVIE
Cardiovalve
HighLife SAS
Neovasc
MitrAssist Lifesciences
Shanghai NewMed Medical
Peijia Medical
MicroPort CardioFlow Medtech
Key Questions Addressed in this Report
What is the 10-year outlook for the global Mitral Valve Intervention market?
What factors are driving Mitral Valve Intervention market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Mitral Valve Intervention market opportunities vary by end market size?
How does Mitral Valve Intervention break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.